At a single academic tertiary referral center, mild intraocular inflammation developed in four eyes following intravitreal ...

In this Healio Video Perspective from Retina 2025, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses positive data for ...

Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients ...

Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a Principal Investigator in PRISM, at Angiogenesis, ...

Faricimab should be readministered with caution in patients who develop mild intraocular inflammation with a previous dose of ...

Canaccord rates Opthea a buy with a $1.25 price target. But the broker thinks it could shoot as high as ... Read More The ...

Pycnogenol French maritime pine bark extract as part of a healthier lifestyle contributes to the reduction of high blood ...

We recently compiled a list of the 12 Best Blue Chip Stocks to Buy Under $100. In this article, we are going to take a look ...

Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...

We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at ...

The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target cut by research analysts at Piper Sandler from $1,195.00 to $1,013.00 in a report issued on Monday,Benzinga reports. The ...